Thursday, February 23, 2012
|
|
| News Archive |
OGT Signs Licensing Deal for Colorectal Cancer Biomarkers
Thursday, February 23, 2012
OGT has entered into an exclusive licensing agreement with Inven2.
JHS Secures Multi-Million Dollar Contracts to Manufacture Sterile Parenteral Products
Thursday, February 23, 2012
Company has secured contracts with four innovator life science companies.
Boehringer Ingelheim and Xencor Enter a Collaboration Agreement
Thursday, February 23, 2012
Antibodies engineered with Xencor’s proprietary Xtend™ technology for increasing antibody half-life.
Shire Announces European Approval of Manufacturing Facility for VPRIV®
Thursday, February 23, 2012
EMA approval adds significant capacity for the manufacture of Shire’s enzyme replacement therapies.
Transcriptional and Posttranscriptional Regulation of HIV-1 Gene Expression
Thursday, February 23, 2012
The transcription factors that control YAP gene expression are unknown. This study demonstrates that ß-catenin/TCF4 complexes bind a DNA enhancer element within the first intron of the YAP gene to drive YAP expression in CRC cells.
Cholinesterases, a Target of Pharmacology and Toxicology
Thursday, February 23, 2012
This review’s main focus is on cholinesterases as targets of toxins and drugs. The biochemistry of AChE and BuChE is also discussed. Drugs and toxins are divided in chapters according to target sites.
Theratechnologies Announces a Supply, Distribution and Licensing Agreement with Actelion
Thursday, February 23, 2012
Agreement provides Actelion with the exclusive commercialization rights to tesamorelin in Canada.
Launch of DIRECT - An Innovative Medicines Initiative Project for Personalized Medicine in Diabetes
Thursday, February 23, 2012
Academia and the pharmaceutical industry working together in the fight against diabetes.
Estimation of drug-metabolizing capacity by CYP-genotyping and CYP-expression
Thursday, February 23, 2012
The lack of therapeutic effect of drugs or the appearance of undesired side-effects is partly caused by differences or changes in drug metabolism. This work aims to introduce an approach of combining CYP-genotyping and CYP-phenotyping tools to estimate patients’ drug-metabolizing capacity.
|
|
|
| << | 1 2 3 4 5 6 7 | >> | | Showing Results 1 - 10 of 18035 |
|
|
